-
Obstetrics and Gynecology Mar 1992Vulvar squamous carcinoma is an uncommon neoplasm that afflicts a spectrum of women and has been associated with granulomatous vulvar diseases, human papillomaviruses... (Review)
Review
Vulvar squamous carcinoma is an uncommon neoplasm that afflicts a spectrum of women and has been associated with granulomatous vulvar diseases, human papillomaviruses (HPVs), and chronic inflammatory disorders of the vulva. This review summarizes the epidemiologic, histopathologic, and viral data supporting the division of invasive vulvar carcinomas into distinct subsets. Although HPVs have received attention as etiologic agents, histopathologic and viral data indicate that a substantial proportion of vulvar carcinomas in this country may not be related to a veneareally transmitted agent. One of the principal challenges is to produce studies integrating the various disciplines in order to place HPV in proper perspective and develop strategies to identify women at risk for vulvar carcinomas that are not associated with this virus.
Topics: Female; Humans; Papillomaviridae; Risk Factors; Sexually Transmitted Diseases; Tumor Virus Infections; Vulvar Diseases; Vulvar Neoplasms
PubMed: 1310806
DOI: 10.1097/00006250-199203000-00025 -
International Journal of Gynecological... Jan 2018Extramammary Paget disease of the vulva (EPDV) is a rare occurrence with an indolent and relapsing course. Progression to invasion occurs in 4% to 19% of cases. The aim...
OBJECTIVE
Extramammary Paget disease of the vulva (EPDV) is a rare occurrence with an indolent and relapsing course. Progression to invasion occurs in 4% to 19% of cases. The aim of this study is to report clinical-pathological features and outcomes of patients treated for invasive EPDV.
METHODS
Data of consecutive patients treated between 2000 and 2017 for invasive EPDV were reviewed.
RESULTS
Among 79 patients with EPDV, 10 (12.7%) presented a microinvasive or invasive form at first diagnosis or during follow-up. All of them underwent upfront radical surgery; 7 (70%) received subsequent radiotherapy, chemotherapy, or both. The mortality rate was 40%. The recurrence rate after treatment for invasive forms was 60%, with a mean time to first recurrence of 20 (range, 5-36) months.
CONCLUSIONS
Our study confirms that invasive EPDV remains a rare gynecological neoplasm with a poor prognosis. Multicentre trials or well-organized prospective data collection could improve the knowledge about the management of invasive EPDV.
Topics: Aged; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Paget Disease, Extramammary; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome; Vulvar Neoplasms
PubMed: 28976448
DOI: 10.1097/IGC.0000000000001131 -
Gynecologic Oncology Sep 1996A rare case of a slowly growing vulvar tumor in a 75-year-old woman is presented. This vulvar neoplasm was an eccrine porocarcinoma with left inguinal nodal metastases.... (Review)
Review
A rare case of a slowly growing vulvar tumor in a 75-year-old woman is presented. This vulvar neoplasm was an eccrine porocarcinoma with left inguinal nodal metastases. This is believed to be only the second reported case of a vulvar eccrine porocarcinoma. Treatment included a left hemivulvectomy, bilateral inguinal-femoral lymphadenectomy, and postoperative radiation therapy. A review of the literature regarding this unusual malignancy is included.
Topics: Acrospiroma; Aged; Female; Groin; Humans; Lymph Node Excision; Radiotherapy, Adjuvant; Thigh; Vulva; Vulvar Neoplasms
PubMed: 8812539
DOI: 10.1006/gyno.1996.0255 -
Zhonghua Bing Li Xue Za Zhi = Chinese... Jan 2010To study the clinicopathological features, immnophenotype and differential diagnosis of prepubertal-type vulva fibroma (PVF). (Review)
Review
OBJECTIVE
To study the clinicopathological features, immnophenotype and differential diagnosis of prepubertal-type vulva fibroma (PVF).
METHOD
Clinical, radiological and pathological features of 2 cases of PVF were analyzed along with a literature review.
RESULTS
Both patients were females of 8.5 and 54 years of age, presented with recurrent unilateral mass at the labium major respectively. Grossly, cut surface of the tumor appeared as the gray fibrous tissue without any definited lump detected. Histologically, the ill-circumscribed lesion located predominantly in the deep dermis with an extension into the subcutaneous tissue. They had a low cell density consisting of scattered spindle shaped fibroblast-like cells and a large amount of collagen fiber matrix, nuclear atypia not seen and mitotic figures scanty. The tumor cells extended downward under the epithelium and infiltrated between the fat tissue, nerve fibers as well as the capillaries making a lesion looked somewhat like a harmatoma. Immunohistochemically, the spindle cells were uniformly positive for vimentin, weakly positive for CD34, and negative for alpha-smooth muscle actin (SMA), muscle specific actin (HHF35), desmin, h-caldesmon, CD99, S-100 protein, bcl-2, beta-catenin, estrogen and progesterone receptors.
CONCLUSIONS
PVF is a benign mesenchymal lesion with a predilection of involving the vulva of prepubertal girls or adults in rare cases. PVF may represent an overgrowth of normal stromal tissue of vulva. Approximately one third of the tumors develop local recurrence due to incomplete excision, however, there is also occasionally spontaneous regression.
Topics: Antigens, CD34; Child; Diagnosis, Differential; Female; Fibroma; Humans; Middle Aged; Myxoma; Neoplasm Recurrence, Local; Vimentin; Vulva; Vulvar Neoplasms
PubMed: 20388398
DOI: No ID Found -
Journal of Obstetrics and Gynaecology :... Oct 2004
Topics: Adult; Female; Granular Cell Tumor; Humans; Vulvar Neoplasms
PubMed: 15763807
DOI: 10.1080/01443610400009675 -
The American Journal of Dermatopathology Apr 2015Extramammary Paget disease of the vulva accounts for 1%–2% of the neoplasms of the anogenital area. Very rarely, extramammary Paget disease of the vulva has been... (Review)
Review
Extramammary Paget disease of the vulva accounts for 1%–2% of the neoplasms of the anogenital area. Very rarely, extramammary Paget disease of the vulva has been associated with an underlying mammary-like carcinoma, usually ductal, extremely rarely mixed ductal and lobular. We report the case of a 60-year-old female with a recurrent extramammary Paget disease of the vulva. Pathological examination of the wide excision of the vulva revealed an extramammary Paget disease with an underlying invasive carcinoma composed of medium size cells organized in single files, a morphology similar to that of an invasive lobular breast carcinoma. Immunohistochemical staining showed a comparable profile in the Paget cells and in the invasive tumoral cells: CEA and CK7 positivity; GCDFP-15, ER focal positivity. E-cadherin and HER2 were diffusely positive. S100 and CK20 were negative. HER2-CISH was amplified. The diagnosis of extramammary Paget disease of the vulva with an underlying mammary-like lobular carcinoma was made. Despite the characteristic lobular features, the immunohistochemical profile differs from the typical profile of a lobular carcinoma of the breast. The implications in term of prognostic and therapeutic significance need to be further studied.
Topics: Animals; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Carcinoma, Lobular; Choristoma; Female; Humans; Immunohistochemistry; Mammary Glands, Human; Middle Aged; Neoplasm Recurrence, Local; Paget Disease, Extramammary; Vulvar Neoplasms
PubMed: 24752217
DOI: 10.1097/DAD.0000000000000065 -
The Journal of Obstetrics and... May 2014Squamous cell vulvar cancer is a rare gynecologic malignancy. Standard treatment for early stage disease consists of wide radical excision of the primary tumor with... (Review)
Review
Squamous cell vulvar cancer is a rare gynecologic malignancy. Standard treatment for early stage disease consists of wide radical excision of the primary tumor with inguinal-femoral lymphadenectomy or sentinel lymph node mapping/biopsy. Because of the general paucity of patients with advanced vulvar cancer, there is no standard therapy for advanced disease and therefore treatment should be individualized. Intergroup trials are needed to clarify the value of chemoradiation, neoadjuvant chemotherapy and targeted therapy in patients with advanced squamous cell cancer of the vulva to identify modalities with the best therapeutic index and lowest morbidity.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Humans; Lymph Node Excision; Neoplasm Staging; Postoperative Complications; Vulvar Neoplasms
PubMed: 24750413
DOI: 10.1111/jog.12352 -
Journal of Cancer Research and... 2019The aim of this study was to evaluate the patterns of recurrence and outcomes in patients with vulvar cancer treated with surgery, with or without postoperative...
AIM
The aim of this study was to evaluate the patterns of recurrence and outcomes in patients with vulvar cancer treated with surgery, with or without postoperative radiotherapy (RT) or RT alone.
MATERIALS AND METHODS
The hospital records were retrospectively analyzed from February 2007 to May 2016. All patients that had biopsy-proven carcinoma vulva were included for analysis. Surgery was done by simple or radical vulvectomy with or without lymph node dissection. Radical RT dose was 60 Gy (photons alone or with electron boost). Adjuvant RT was administered in case of node positivity or positive margins.
RESULTS
A total of 76 patients were diagnosed as squamous cell carcinoma of vulva. The median age was 59 years. About 59 patients were treated by surgery and 17 patients were treated by radical RT. The most common stage was IB. Adjuvant RT was administered in 10 patients. About 13 patients (22%) underwent inguinal lymphadenectomy. At a median follow-up of 35 months, 49 patients (64.4%) were alive, 27 died, and 6 patients were lost to follow-up. Locoregional recurrence rate was 24.5% in radical surgery group, 12% in surgery plus adjuvant RT group, and 47% in radical RT group. Distant metastasis rate was 4%. The progression-free survival at 3 years was 45.3% and 35.5% in the surgery group and radical RT group, respectively.
CONCLUSION
Surgery resulted in favorable local control rates in early-stage carcinoma vulva. Adjuvant RT is indicated in case of nodal positivity or positive margins. Radical RT can be considered as an alternative in patients with comorbidities.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Combined Modality Therapy; Female; Histocytochemistry; Humans; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Vulvar Neoplasms
PubMed: 31898668
DOI: 10.4103/jcrt.JCRT_44_18 -
American Journal of Obstetrics and... Apr 1970
Topics: Adult; Aged; Amputation, Surgical; Carcinoma, Squamous Cell; Cardiovascular Diseases; Female; Hepatitis; Humans; Iatrogenic Disease; Lymph Node Excision; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Peripheral Nerve Injuries; Phlebitis; Postoperative Complications; Prognosis; Pulmonary Embolism; Surgical Wound Infection; Urinary Tract Infections; Vulva; Vulvar Neoplasms
PubMed: 5437811
DOI: 10.1016/0002-9378(70)90506-5 -
The American Journal of Dermatopathology Aug 2013Mammary-like vulvar carcinoma represents an extremely rare disease. Here, the authors report a case of mammary-like ductal carcinoma of the vulva. A 71-year-old woman... (Review)
Review
Mammary-like vulvar carcinoma represents an extremely rare disease. Here, the authors report a case of mammary-like ductal carcinoma of the vulva. A 71-year-old woman affected by stage T2N1M0 mammary-like vulvar carcinoma underwent neoadjuvant chemotherapy, radical vulvectomy, and adjuvant antioestrogen hormone therapy. The patient is alive, 24 months after surgery, with no clinical and radiological evidence of disease. To provide a better insight in to the clinical approach for this rare disease, a review of the available literature was performed.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Carcinoma in Situ; Carcinoma, Ductal; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Gynecologic Surgical Procedures; Humans; Immunohistochemistry; Neoadjuvant Therapy; Neoplasm Staging; Time Factors; Treatment Outcome; Vulvar Neoplasms
PubMed: 23518640
DOI: 10.1097/DAD.0b013e31828484c0